Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR108 in hematological malignancies
NCT06018506Phase 1Terminated
- Sponsor
- BioRay Pharmaceutical
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BR108 in lymphoma, acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by BioRay Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days and Objective Response Rate at 3 years. Started Mar 2023; status: terminated.
02
Drugs
BR108
03
Conditions
lymphomaacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06018506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06018506.